Niche Biotech Adeptrix offers discovery-focused bioanalytical services using exoBAMS to profile extracellular vesicles for oncology and complex diseases, presenting a strong value proposition for pharma, biotech, CROs, and academic partners seeking biomarker discovery and translational research opportunities.

Targeted EV Enrichment The unique capability to selectively isolate disease-relevant EV populations before analysis addresses a key pain point in liquid biopsy readouts, enabling clearer molecular signals, better reproducibility, and more interpretable data for decision-making in early research and biomarker prioritization.

Pilot Collaboration Adeptrix emphasizes discovery-driven collaboration with flexible pilot studies and scalable workflows, offering a low-risk path for potential customers to test hypotheses, de-risk early research decisions, and accelerate translational programs.

RUO Platform exoBAMS is designed for research use only, which positions the company well for early-stage partnerships and pilot projects with academia and biotech firms before moving to clinical-grade validation.

Strategic Partnerships Historical partnerships with industry players (e.g., Bruker) and involvement in RADx-funded initiatives signal a favorable environment for co-development, potential joint sales opportunities, and access to broader distribution and market channels.